Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Check-Points Health
Waltham, Massachusetts, United States
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Checkpoint Therapeutics is a commercial-stage immuno-oncology company. Its lead PD‑L1 monoclonal antibody cosibelimab (marketed as UNLOXCYT) has U.S. FDA approval for adults with metastatic or locally advanced cutaneous squamous cell carcinoma not candidates for curative surgery or radiation, and the company is developing additional antibody and small‑molecule oncology programs including olafertinib (EGFR inhibitor) and the anti‑GITR antibody CK‑302 in earlier stages of development.[1][2][3]
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodySmall moleculeBiologic
- Industry
- Biotech
02
Partnerships
Dana-Farber Cancer Institute (license for cosibelimab/UNLOXCYT)[1][2]Adimab (antibody discovery collaboration)[1]NeuPharma (license to develop and commercialize olafertinib)[1]Jubilant Biosys (BET bromodomain inhibitor collaboration)[1]
Beyond the preview
Go deeper on Check-Points Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Check-Points Health.